RESEARCH TRIANGLE PARK, N.C., March 15, 2010 – Quintiles today announced that it has successfully relocated its Global Central Laboratory in Japan from Saitama to Tokyo to allow for expansion as Quintiles’ business in Japan and Asia-Pacific continues to grow.
The new wholly owned Quintiles facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples on March 1, and has already received National Glycohemoglobin Standardization Program Level 1 certification for diabetes testing.
“The growth of clinical research in Asia-Pacific is driving this move as we continue to reduce complexity and help our customers get new medicines to patients faster,” said Alan Ong, Vice President and General Manager, Quintiles Global Central Laboratories Asia. “We are building on a strong record of high quality and outstanding customer service, and with an expanding test menu, it makes sense to move into new facilities that provide room for growth.”
Quintiles Global Central Laboratories is a leader in developing novel biomarker assays to support clinical development of targeted therapies and other personalized medicine advances. Today, at labs in China, Scotland and the United States, Quintiles can perform Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) testing. Quintiles’ biomarker tests are used to target genes that affect cancer cell growth and mutation.
The new Japan lab is taking steps toward certification by the College of American Pathologists (CAP). Quintiles has the largest CAP-certified central laboratory network in the world, with other wholly owned facilities in the U.S., Europe, South Africa, India, China and Singapore, and a tightly controlled network of affiliate laboratories in Argentina and Brazil. The network recently expanded its anatomical pathology capability in China.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.